No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NMRA240719P10000
- 1.45
- 0.000.00%
15min DelayClose Jun 21 10:38 ET
0.00High0.00Low
0.00Open1.45Pre Close0 Volume15 Open Interest10.00Strike Price0.00Turnover4775.14%IV26.36%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry1.45Extrinsic Value100Contract SizeAmericanOptions Type-0.3118Delta0.0650Gamma8.01Leverage Ratio-26.4981Theta0.0000Rho-2.50Eff Leverage0.0004Vega
Intraday
- 5D
- Daily
News
Needham Initiates Neumora Therapeutics(NMRA.US) With Buy Rating, Announces Target Price $23
Needham analyst Ami Fadia initiates coverage on $Neumora Therapeutics(NMRA.US)$ with a buy rating, and sets the target price at $23.According to TipRanks data, the analyst has a success rate of 47.4%
Needham Initiates Coverage On Neumora Therapeutics With Buy Rating, Announces Price Target of $23
Needham analyst Ami Fadia initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and announces Price Target of $23.
Express News | Neumora Therapeutics Inc : Needham Initiates Coverage With Buy Rating; Target Price $23
Express News | Neumora Therapeutics Shares Are Trading Higher After Mizuho Initiated Coverage on the Stock With an Outperform Rating and Announced a $20 Price Target
Mizuho Securities Initiates Neumora Therapeutics(NMRA.US) With Buy Rating, Announces Target Price $20
Mizuho Securities analyst Graig Suvannavejh initiates coverage on $Neumora Therapeutics(NMRA.US)$ with a buy rating, and sets the target price at $20.According to TipRanks data, the analyst has a
Neumora Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 95.12% Mizuho → $20 Initiates Coverage On → Outperform 03/28/2024 202.44% RBC Capital → $31 Rei
Comments
Ms. Pai Panandiker's appointment, with her vast neuropsychiatry commercial expertise, is seen as invaluable for Neumora's potential commercialization of navacaprant and pipeline advancement. Her experience in neuroscience product commercialization is expected to boost Neumora's growth.
Press Release: Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer 1
CEO of Neumora Therapeutics is optimistic over Mr. Duncan's appointment due to his legal expertise and program strategy, valuable to the company's goal of advancing neuroscience drug development. Duncan highlights Neumora's leading brain disorder pipeline and recent clinical progress.
CEO of Neumora, Henry Gosebruch, values Dr. Lenz's successful trial experience and neuroscience expertise for their pipeline development. Dr. Lenz is excited to contribute significantly to Neumora's R&D and neuropsychiatry programs.
$Axcella Health(AXLA.US$ Ranked #1 by Fintel. Its next run should take it to about 14.90.
$Ontrak(OTRK.US$ Has been out of shares for a week. Small float and cheap price. Can run as high as 2.94 when it finally does get volume.
$Neumora Therapeutics(NMRA.US$ Recent IPO and has been steady moving up from its low of 9.80. Now comes the bigger gap ups . 17.74 is its breakout.
$Prestige Wealth(PWM.US$ Seems to have found bottom at 3.10. If it has ER on October 6 that is. S...
$Ontrak(OTRK.US$ Has been out of shares for a week. Small float and cheap price. Can run as high as 2.94 when it finally does get volume.
$Neumora Therapeutics(NMRA.US$ Recent IPO and has been steady moving up from its low of 9.80. Now comes the bigger gap ups . 17.74 is its breakout.
$Prestige Wealth(PWM.US$ Seems to have found bottom at 3.10. If it has ER on October 6 that is. S...
7
9
McHTP
Read more